A Multicenter, Randomized, Open-Label, Active-Controlled, Trial to Evaluate the Safety and Efficacy of Rifaximin 550 mg With and Without Lactulose in Subjects With a History of Recurrent Overt Hepatic Encephalopathy
Phase of Trial: Phase IV
Latest Information Update: 12 Sep 2019
Price : $35 *
At a glance
- Drugs Rifaximin (Primary) ; Lactulose
- Indications Hepatic encephalopathy
- Focus Therapeutic Use
- Sponsors Bausch Health Companies; Salix Pharmaceuticals
- 13 Jul 2018 According to a Bausch Health Companies media release, Valeant Pharmaceuticals International changed its name to Bausch Health Companies.
- 15 Jul 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 14 May 2014 New source identified and integrated (Mayo Clinic; IRB13-000483).